A stent-free future? How drug-coated balloons transform angioplasty care

For decades, metal stents have been the backbone of angioplasty, propping open narrowed arteries and restoring blood flow in heart disease patients. But as cardiology increasingly focuses on long-term vessel health rather than just immediate results, a new approach is gaining ground: drug-coated balloon (DCB) angioplasty, a strategy built on the principle of “leave nothing behind”.

Globally, the shift is being driven by concerns over complications linked to permanent metal implants, including chronic inflammation, loss of natural vessel movement and repeat blockages over time. Drug-coated balloons, which deliver medication to the artery wall and are then removed, aim to reduce these risks while allowing blood vessels to heal and function more naturally.

Firstpost spoke to leading experts to explore how this technology is revolutionising the operating room.

How drug-coated balloons work

Drug-coated balloons are designed to treat blocked arteries without leaving a permanent scaffold behind. During the procedure, the balloon is inflated at the site of narrowing, releasing anti-proliferative medication that limits abnormal tissue growth, a major cause of artery re-narrowing. Once deflated and removed, no foreign material remains inside the vessel.

According to Dr. Aditi Dattagupta, Consultant – Interventional Cardiology, SPARSH Hospital (Bangalore), this “leave nothing behind” approach addresses many long-term issues seen with metal stents. Because DCBs do not stay in the artery, they reduce the risk of chronic inflammation and make future medical or surgical interventions easier if required.

More from Health

Doctor explains: Why younger, non-diabetics are being diagnosed with pancreatic cancer Omega-3 deficiency emerging as a major risk to heart and metabolic health: Experts

Another key advantage is preservation of natural vessel movement. Without a rigid metal structure, arteries can continue to expand and contract normally, which is particularly beneficial for younger patients and those who may need additional cardiac procedures later. DCB angioplasty has also been shown to lower restenosis rates in selected lesions, while not interfering with bypass surgery or repeat angioplasty in the future.

Where DCBs offer clear advantages and where they don’t

DCBs are emerging as an attractive option in carefully selected cases, especially for patients with small vessel disease or those experiencing in-stent restenosis, where adding another metal stent may not be ideal.

Dr. Gopi A, Senior Director, Cardiology at Fortis Hospital (Bengaluru) said that by delivering medication directly during balloon inflation and leaving no implant behind, DCBs help avoid long-term complications associated with stents including tissue overgrowth and restricted vessel flexibility. This allows arteries to maintain their natural ability to expand and contract, an important factor for long-term vascular health.

Quick Reads

View All

Vibration plates are the newest trend in fitness. Are they of any help though?

Decades of nuclear tests linked to 4 mn premature deaths globally, report says

However, both experts emphasised that DCBs are not suitable for all patients. One of the main risks is arterial dissection during balloon inflation, which can suddenly compromise blood flow. Stents were originally developed to solve this problem by acting as a scaffold to hold arteries open.

The success of DCB angioplasty depends heavily on careful lesion assessment, proper vessel preparation and patient selection. Outcomes are closely linked to procedural expertise, making it essential that such interventions are carried out by experienced teams following strict protocols.

While stents continue to play a critical role in many cases, drug-coated balloons represent a significant step towards more natural, adaptable coronary interventions, indicating a future where restoring vessel health may mean leaving nothing behind at all.

Preserving future options and flexibility

One of the most significant advantages of a stent-free intervention is the flexibility it offers, both for the artery and for future medical needs. Because no metal scaffold is left behind, the blood vessel retains its “vasomotion,” or the ability to react to physical stress by expanding or contracting.

According to Dr. Dattagupta, this preserves the natural flexibility of any artery in the body. “Since no metal scaffold is left behind, the vessel continues to expand and contract normally, which is beneficial for younger patients and those who may require future cardiac procedures,” she said. Furthermore, DCBs do not interfere with bypass surgery or repeat angioplasty if needed later, as there is no metallic obstruction in the way.

Dr. Gopi said that this technology is a “useful option in carefully chosen cases where preserving vessel structure and flexibility is a priority.” It is increasingly becoming the go-to choice for small vessel disease or cases where a previously placed stent has failed (in-stent restenosis), scenarios where adding more metal might be counterproductive.

The vital caveat: Careful selection is key

Despite the excitement surrounding a “stent-free” world, experts warn that DCBs are not a universal replacement for all patients. The procedure requires high technical precision and meticulous preparation.

“It is not necessary that Drug-Coated Balloons are suitable for each and every patient,” warns Dr. Dattagupta. She pointed out a specific risk of arterial dissection (a tear in the artery wall) if the vessel is not prepared properly. Because of this, she stressed that DCB angioplasty should only be performed by experienced teams following strict medical protocols.

Dr. Gopi said that stents were first designed as a support to stop sudden blockages caused by dissections. “The success of DCBs depends on the type of blockage and how the artery responds during treatment,” he said. “While stents remain essential in many cases, Drug-Coated Balloons represent an important step toward more natural and adaptable coronary interventions.”